Journal article
Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial
Abstract
AIMS: Secondary prevention in patients with coronary artery disease and peripheral artery disease involves antithrombotic therapy and optimal control of cardiovascular risk factors. In the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) study, adding low-dose rivaroxaban on top of aspirin lowered cardiovascular events, but there is limited data about risk factor control in secondary prevention. We studied the …
Authors
Vanassche T; Verhamme P; Anand SS; Shestakovska O; Fox KA; Bhatt DL; Avezum A; Alings M; Aboyans V; Maggioni AP
Journal
European Journal of Preventive Cardiology, Vol. 27, No. 3, pp. 296–307
Publisher
Oxford University Press (OUP)
Publication Date
February 2020
DOI
10.1177/2047487319882154
ISSN
2047-4873
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AgedAnticoagulantsAspirinChronic DiseaseCoronary Artery DiseaseDouble-Blind MethodDrug Therapy, CombinationFactor Xa InhibitorsFemaleFibrinolytic AgentsHeart Disease Risk FactorsHumansMaleMiddle AgedPeripheral Arterial DiseaseProspective StudiesRecurrenceRisk AssessmentRivaroxabanSecondary PreventionTime FactorsTreatment Outcome